Sage Therapeutics(SAGE) - 2023 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a net loss of $32.7 million for Q4 2023 and ended the quarter with approximately $753 million in cash, cash equivalents, and marketable securities [11] - Collaboration revenue from ZURZUVAE was $824,000 in Q4 2023, representing 50% of the net sales recorded by Biogen [31][35] - A milestone revenue of $75 million was recognized from Biogen related to the first commercial sale of ZURZUVAE for PPD treatment [35] Business Line Data and Key Metrics Changes - ZURZUVAE generated initial demand with 120 prescriptions written in the first 10 days post-launch, indicating strong engagement from healthcare providers across various specialties [19][31] - The company aims to establish ZURZUVAE as the first-line therapy for women suffering from postpartum depression (PPD) [7][32] Market Data and Key Metrics Changes - The prescribing behavior for ZURZUVAE is broad, with prescriptions coming from psychiatrists, OB-GYNs, and primary care providers, reflecting a shift in the treatment approach for PPD [2][19] - The company is seeing a paradigm shift where healthcare providers are diagnosing and treating PPD rather than merely referring patients [66][84] Company Strategy and Development Direction - The company is focused on making ZURZUVAE accessible and affordable, with initiatives like the "ZURZUVAE For You" patient assistance program to mitigate out-of-pocket costs for patients [27][44] - The company is advancing its pipeline, particularly with Dalzanemdor, a potential treatment for cognitive disorders associated with neurodegenerative diseases [8][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch of ZURZUVAE, noting that demand continues to grow into early 2024 without signs of a warehousing effect [62][85] - The company plans to provide further updates on the commercial trajectory of ZURZUVAE as more data becomes available [85] Other Important Information - The company is preparing for a catalyst-rich 2024 with multiple expected data readouts for Dalzanemdor and SAGE-324, aiming to strengthen its leadership position in brain health [117] - The company emphasizes the importance of addressing maternal mental health treatment disparities and the growing recognition of PPD as a serious medical condition [106] Q&A Session Summary Question: Can you share the split between commercial and Medicaid for the 120 scripts? - Management noted that they cannot provide specific splits at this time but are encouraged by the initial activity [12][37] Question: What are the key gating factors for SAGE-718? - Management discussed the importance of understanding the competitive landscape and the need to demonstrate safety and efficacy as they move into Phase 3 [16][41] Question: How is the free drug program working? - The program has been effective in ensuring that patients with commercial insurance pay $0 out of pocket, and it is also available for functionally uninsured patients [27][44] Question: What feedback are you receiving from patients on ZURZUVAE? - Early feedback has been positive, with reports of ZURZUVAE performing as expected based on clinical trials [58] Question: Why is there no revenue guidance for ZURZUVAE for 2024? - Management indicated that they need more time to understand the dynamics around uptake before providing guidance [85]